Ratings Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Real-time Estimate Cboe BZX 03:27:33 2024-02-22 pm EST 5-day change 1st Jan Change
23.16 USD +1.09% Intraday chart for Myriad Genetics, Inc. -1.95% +20.85%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
+20.85% 2 031 M $
C
+3.83% 13 335 M $
B+
-4.45% 8 205 M $
B-
-18.53% 5 554 M $
D+
-0.11% 5 354 M $
B
+2.53% 4 610 M $
C
+4.17% 3 884 M $
C
+6.42% 2 621 M $ - -
-4.21% 2 460 M $
B-
+3.19% 1 598 M $ -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer